Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: An Italian multi-institutional phase II trial (401 views)
Neuro-Oncology (ISSN: 1522-8517), 2014 May; 16(5): 748-753.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 6.776, 5-year impact factor: 6.604
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84899437120&partnerID=40&md5=b26db4c05154847234c3c954ac57948b
Keywords: Medulloblastoma, Phase Ii Trial, Temozolomide, Antiemetic Agent, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Methotrexate, Nitrosourea Derivative, Vincristine, Adolescent, Adult, Anemia, Article, Bone Marrow Suppression, Cancer Chemotherapy, Cancer Growth, Chemotherapy Induced Nausea And Vomiting, Child, Childhood Cancer, Clinical Article, Craniospinal Irradiation, Drug Dose Reduction, Drug Efficacy, Drug Tolerability, Female, Histology, Human, Italy, Maintenance Chemotherapy, Multicenter Study, Neuroectoderm Tumor, Neutropenia, Overall Survival, Phase 2 Clinical Trial, Progression Free Survival, Thrombocytopenia, Treatment Response, Tumor Recurrence, Tumor Volume, Unspecified Side Effect,
Affiliations:
*** IBB - CNR ***
Pediatrics Unit, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
Pediatric Oncology, A. Gemelli Hospital, Catholic University, Rome, Italy
Department of Radiodiagnostics, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
Department of Neurosurgery, Ospedale G. Gaslini, Genova, Italy
Department of Pediatrics, University of Padua, Padua, Italy
Department of Bioimaging and Radiological Sciences, Catholic University, Rome, Italy
References:
Not available.
Neuro-Oncology (ISSN: 1522-8517), 2014 May; 16(5): 748-753.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 6.776, 5-year impact factor: 6.604
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84899437120&partnerID=40&md5=b26db4c05154847234c3c954ac57948b
Keywords: Medulloblastoma, Phase Ii Trial, Temozolomide, Antiemetic Agent, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Methotrexate, Nitrosourea Derivative, Vincristine, Adolescent, Adult, Anemia, Article, Bone Marrow Suppression, Cancer Chemotherapy, Cancer Growth, Chemotherapy Induced Nausea And Vomiting, Child, Childhood Cancer, Clinical Article, Craniospinal Irradiation, Drug Dose Reduction, Drug Efficacy, Drug Tolerability, Female, Histology, Human, Italy, Maintenance Chemotherapy, Multicenter Study, Neuroectoderm Tumor, Neutropenia, Overall Survival, Phase 2 Clinical Trial, Progression Free Survival, Thrombocytopenia, Treatment Response, Tumor Recurrence, Tumor Volume, Unspecified Side Effect,
Affiliations:
*** IBB - CNR ***
Pediatrics Unit, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
Pediatric Oncology, A. Gemelli Hospital, Catholic University, Rome, Italy
Department of Radiodiagnostics, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy
Department of Neurosurgery, Ospedale G. Gaslini, Genova, Italy
Department of Pediatrics, University of Padua, Padua, Italy
Department of Bioimaging and Radiological Sciences, Catholic University, Rome, Italy
References:
Not available.
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: An Italian multi-institutional phase II trial
BackgroundThe aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.MethodsForty-two patients with recurrent MB/PNET, aged 21 years and younger, were recruited. Patients were treated with oral TMZ. Starting doses ranged from 120 to 200 mg/m 2/day based on previous treatments. A craniospinal MRI was performed prior to the first cycle of TMZ and following every 2 cycles of treatment.ResultsMedian age was 10 years (range, 2-21 years). Forty of 42 patients were assessed for response and toxicity. The objective response rate was 42.5%: 6 patients achieved a complete response, 11 had a partial response, and 10 had stable disease. Progression-free survival rates for all patients at 6 and 12 months were 30% and 7.5%, respectively. Their median overall survival rates at 6 and 12 months were 42.5% and 17.5%, respectively. No major extrahematological effects or life-threatening events were reported. The most common grade 3/4 toxicity included thrombocytopenia (17.5%), neutropenia (7.5%), and anemia (2.5%).ConclusionsTMZ proved to be an effective agent in children and young adults with MB/PNET, heavily pre-treated, with a tolerable toxicity profile. © 2014 © The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
BackgroundThe aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.MethodsForty-two patients with recurrent MB/PNET, aged 21 years and younger, were recruited. Patients were treated with oral TMZ. Starting doses ranged from 120 to 200 mg/m 2/day based on previous treatments. A craniospinal MRI was performed prior to the first cycle of TMZ and following every 2 cycles of treatment.ResultsMedian age was 10 years (range, 2-21 years). Forty of 42 patients were assessed for response and toxicity. The objective response rate was 42.5%: 6 patients achieved a complete response, 11 had a partial response, and 10 had stable disease. Progression-free survival rates for all patients at 6 and 12 months were 30% and 7.5%, respectively. Their median overall survival rates at 6 and 12 months were 42.5% and 17.5%, respectively. No major extrahematological effects or life-threatening events were reported. The most common grade 3/4 toxicity included thrombocytopenia (17.5%), neutropenia (7.5%), and anemia (2.5%).ConclusionsTMZ proved to be an effective agent in children and young adults with MB/PNET, heavily pre-treated, with a tolerable toxicity profile. © 2014 © The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: An Italian multi-institutional phase II trial
| ▼ Characterization of the KCTD protein family: key factors in several biological processes |
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: An Italian multi-institutional phase II trial
Other filter: ([btitle,keywords] "Medulloblastoma" OR ...
Ferrucci V, De Antonellis P, Pennino FP, Asadzadeh F, Virgilio A, Montanaro D, Galeone A, Boffa I, Pisano I, Scognamiglio I, Navas L, Diana D, Pedone E, Gargiulo S, Gramanzini M, Brunetti A, Danielson L, Carotenuto M, Liguori L, Verrico A, Quaglietta L, Errico ME, Del Monaco V, D'Argenio V, Tirone F, Mastronuzzi A, Donofrio V, Giangaspero F, Picard D, Remke M, Garzia L, Daniels C, Delattre O, Swartling FJ, Weiss WA, Salvatore F, Fattorusso R, Chesler L, Taylor MD, Cinalli G, Zollo M
* Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-beta-OTX2-SNAIL via PTEN inhibition (1411 views)
Brain (ISSN: 1460-2156electronic, 0006-8950linking), 2018 May 1; 141(5): 1300-1319.
Impact Factor: 9.915
View Export to BibTeX Export to EndNote
Picone D, Donnarumma F, Ferraro G, Gotte G, Fagagnini A, Butera G, Donadelli M, Merlino A
* A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin (351 views)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2017 Aug; 173: 105-112.
Impact Factor: 3.063
View Export to BibTeX Export to EndNote
Pontillo N, Ferraro G, Helliwell JR, Amoresano A, Merlino A
* X-ray Structure of the Carboplatin-Loaded Apo-Ferritin Nanocage (246 views)
Acs Med Chem Lett (ISSN: 1948-5875, 1948-5875linking), 2017 Feb 28; 8(4): 433-437.
Impact Factor: 3.794
View Export to BibTeX Export to EndNote
Crisci V, Mainenti PP, Corvino F, Lauria R, Maurea S
* Bone involvement by adenocarcinoma of the uterine cervix: a rare entity (798 views)
Pol J Radiol (ISSN: 0137-7183, 1733-134x, 1733-134xlinking), 2015 Feb 14; 80(1): 81-84.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Messori L, Marzo T, Merlino A
* Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts (353 views)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2015; N/D: N/D-N/D.
Impact Factor: 3.205
View Export to BibTeX Export to EndNote
Insabato L, Natella V, Somma A, Persico M, Camera L, Losito NS, Masone S
* Primary Peritoneal Clear Cell Carcinoma Versus Ovarian Carcinoma Versus Malignant Transformation of Endometriosis: A Vexing Issue (314 views)
Int J Surg Pathol (ISSN: 1066-8969), 2015; 23(3): 211-216.
Impact Factor: 0.782
View Export to BibTeX Export to EndNote
Pedicini P, Fiorentino A, Simeon V, Tini P, Chiumento C, Pirtoli L, Salvatore M, Storto G
* Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes (400 views)
Strahlenther Onkol (ISSN: 0179-7158, 0179-7158linking), 2014 Oct; 190(10): 925-932.
Impact Factor: 2.914
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (405 views)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
View Export to BibTeX Export to EndNote
Correale S, Pirone L, Di Marcotullio L, De Smaele E, Greco A, Mazzà D, Moretti M, Alterio V, Vitagliano L, Di Gaetano S, Gulino A, Pedone E
* Molecular organization of the cullin E3 ligase adaptor KCTD11 (596 views)
Biochimie (ISSN: 0300-9084, 1638-6183, 1638-6183electronic), 2011 Apr; 93(4): 715-724.
Impact Factor: 3.022
View Export to BibTeX Export to EndNote
Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, Ferretti E, Miele E, Pelloni M, De Simone G, Pedone E, Gallinari P, Giorgi A, Steinkuhler C, Vitagliano L, Pedone C, Schinin ME, Screpanti I, Gulino A
* Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation (721 views)
Nature Cell Biol Nature Cell Biology (ISSN: 1476-4679, 1465-7392), 2010 Feb; 12(2): 132-142.
Impact Factor: 19.407
View Export to BibTeX Export to EndNote
Peca C, Pacelli R, Elefante A, Del Basso De Caro ML, Vergara P, Mariniello G, Giamundo A, Maiuri F
* Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: Tumour progression or radionecrosis? (403 views)
Clin Neurol Neurosurg (ISSN: 0303-8467), 2009 May; 111(4): 331-334.
Impact Factor: 1.303
View Export to BibTeX Export to EndNote
Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Del Vecchio L, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M
* MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma (463 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2009 Mar 24; 4(3): e4998-e4998.
Impact Factor: 4.351
View Export to BibTeX Export to EndNote
Miralbell R, Lomax A, Cella L, Schneider U
* Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors (268 views)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2002 Nov 1; 54(3): 824-829.
Impact Factor: 3.756
View Export to BibTeX Export to EndNote
Gridelli C, Manzione L, Perrone F, Veltri E, Cioffi R, Caprio MG, Frontini L, Rossi A, Barletta E, Barzelloni ML, Bilancia D, Gallo C
* Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study (266 views) (PDF 220 views)
Br J Cancer (ISSN: 0007-0920print, 0007-0920linking), 2001 Jan 5; 84(1): 38-41.
Impact Factor: 3.942
View Export to BibTeX Export to EndNote
* Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-beta-OTX2-SNAIL via PTEN inhibition (1411 views)
Brain (ISSN: 1460-2156electronic, 0006-8950linking), 2018 May 1; 141(5): 1300-1319.
Impact Factor: 9.915
View Export to BibTeX Export to EndNote
Picone D, Donnarumma F, Ferraro G, Gotte G, Fagagnini A, Butera G, Donadelli M, Merlino A
* A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin (351 views)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2017 Aug; 173: 105-112.
Impact Factor: 3.063
View Export to BibTeX Export to EndNote
Pontillo N, Ferraro G, Helliwell JR, Amoresano A, Merlino A
* X-ray Structure of the Carboplatin-Loaded Apo-Ferritin Nanocage (246 views)
Acs Med Chem Lett (ISSN: 1948-5875, 1948-5875linking), 2017 Feb 28; 8(4): 433-437.
Impact Factor: 3.794
View Export to BibTeX Export to EndNote
Crisci V, Mainenti PP, Corvino F, Lauria R, Maurea S
* Bone involvement by adenocarcinoma of the uterine cervix: a rare entity (798 views)
Pol J Radiol (ISSN: 0137-7183, 1733-134x, 1733-134xlinking), 2015 Feb 14; 80(1): 81-84.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Messori L, Marzo T, Merlino A
* Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts (353 views)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2015; N/D: N/D-N/D.
Impact Factor: 3.205
View Export to BibTeX Export to EndNote
Insabato L, Natella V, Somma A, Persico M, Camera L, Losito NS, Masone S
* Primary Peritoneal Clear Cell Carcinoma Versus Ovarian Carcinoma Versus Malignant Transformation of Endometriosis: A Vexing Issue (314 views)
Int J Surg Pathol (ISSN: 1066-8969), 2015; 23(3): 211-216.
Impact Factor: 0.782
View Export to BibTeX Export to EndNote
Pedicini P, Fiorentino A, Simeon V, Tini P, Chiumento C, Pirtoli L, Salvatore M, Storto G
* Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes (400 views)
Strahlenther Onkol (ISSN: 0179-7158, 0179-7158linking), 2014 Oct; 190(10): 925-932.
Impact Factor: 2.914
View Export to BibTeX Export to EndNote
Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F
* Complete Response To Preoperative Chemoradiation And Survival In Esophageal Cancer: A Pooled Analysis Of Three Single-Institution Phase Ii Trials (405 views)
Diseases Of The Esophagus, 2012 Feb; 142(5): 130-136.
Impact Factor: 2.057
View Export to BibTeX Export to EndNote
Correale S, Pirone L, Di Marcotullio L, De Smaele E, Greco A, Mazzà D, Moretti M, Alterio V, Vitagliano L, Di Gaetano S, Gulino A, Pedone E
* Molecular organization of the cullin E3 ligase adaptor KCTD11 (596 views)
Biochimie (ISSN: 0300-9084, 1638-6183, 1638-6183electronic), 2011 Apr; 93(4): 715-724.
Impact Factor: 3.022
View Export to BibTeX Export to EndNote
Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, Ferretti E, Miele E, Pelloni M, De Simone G, Pedone E, Gallinari P, Giorgi A, Steinkuhler C, Vitagliano L, Pedone C, Schinin ME, Screpanti I, Gulino A
* Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation (721 views)
Nature Cell Biol Nature Cell Biology (ISSN: 1476-4679, 1465-7392), 2010 Feb; 12(2): 132-142.
Impact Factor: 19.407
View Export to BibTeX Export to EndNote
Peca C, Pacelli R, Elefante A, Del Basso De Caro ML, Vergara P, Mariniello G, Giamundo A, Maiuri F
* Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: Tumour progression or radionecrosis? (403 views)
Clin Neurol Neurosurg (ISSN: 0303-8467), 2009 May; 111(4): 331-334.
Impact Factor: 1.303
View Export to BibTeX Export to EndNote
Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Del Vecchio L, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M
* MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma (463 views)
Plosone (ISSN: 1932-6203, 1932-6203electronic, 1932-6203linking), 2009 Mar 24; 4(3): e4998-e4998.
Impact Factor: 4.351
View Export to BibTeX Export to EndNote
Miralbell R, Lomax A, Cella L, Schneider U
* Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors (268 views)
Int J Radiat Oncol (ISSN: 0360-3016, 1879-355x, 1879-355xelectronic), 2002 Nov 1; 54(3): 824-829.
Impact Factor: 3.756
View Export to BibTeX Export to EndNote
Gridelli C, Manzione L, Perrone F, Veltri E, Cioffi R, Caprio MG, Frontini L, Rossi A, Barletta E, Barzelloni ML, Bilancia D, Gallo C
* Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study (266 views) (PDF 220 views)
Br J Cancer (ISSN: 0007-0920print, 0007-0920linking), 2001 Jan 5; 84(1): 38-41.
Impact Factor: 3.942
View Export to BibTeX Export to EndNote
14 Records (13 excluding Abstracts).
Total impact factor: 62.078 (57.727 excluding Abstracts).
Total 5 year impact factor: 65.291 (60.908 excluding Abstracts).
Total impact factor: 62.078 (57.727 excluding Abstracts).
Total 5 year impact factor: 65.291 (60.908 excluding Abstracts).
401 views. Last view on Monday 27 November 2023, 2:31:12
ibb.cnr.it
